Spaulding Clinical Research, LLC, has partnered with clinicalRSVP (clinical Research Subject Verification Program), a provider of participant registry services aimed at subject safety and data integrity. Spaulding Clinical will join participating clinical sites that use clinicalRSVP to check subject eligibility requirements before dosing begins. The addition of Spaulding Clinical expands the reach of the clinicalRSVP site network and strengthens the network for participating sites.

“Dual enrollment is becoming an incredibly hot topic in the clinical pharmacology circuit as sponsors are becoming very keen to ensure subjects are only in their studies,” said Daniel Selness, general manager and senior vice president of operations at Spaulding Clinical. “Spaulding is pleased to be able to provide this added measure of diligence for our study sponsors.”

“The addition of Spaulding Clinical represents a terrific advancement for clinicalRSVP and for those who sponsor and conduct Phase I trials across North America,” said Darran Boyer, president of clinicalRSVP. “We are pleased that our network now spans from coast to coast, including the Midwest and into Canada. We see the continued growth of this Phase I network as a positive sign of things to come, and we will continue to promote the advancements achieved through clinicalRSVP as we look to join additional Phase I units across the United States and Canada.”